Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab

References

• Fox DA. Biological therapies: a novel approach to the treatment of autoimmune disease. Am J Med. 1995;99:82–8.
   PubMedGoogle Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alfa. Arthritis Rheum. 1993;36: 168 1–90.
   PubMedGoogle Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602): 1861–74.
   Google Scholar
• Matsuno H. Expensive medical expense and cost-reduction strategies in patients with rheumatoid arthritis. Clin Rheumatol Related Res. 2008;39:548-54. (in Japanese; abstract in English).
   Google Scholar
• Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol. 2006;33:2398–408.
   Google Scholar
• Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effect of hydroxychloroquine and sulphasal-azine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036–8.
   PubMed Web of Science ®Google Scholar
• Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16: 585–91.
   Google Scholar
• O'Dell JR. Treating rheumatoid arthritis; a window of opportu-nity? Arthritis Rheum. 2002;46:283–5.
   Google Scholar
• American College of Rheumatology Subcommittee on Rheuma-toid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002; 46:328–46.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Inflixamab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932–9.
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheu-matoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478–86.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheuma-toid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PRE-MIER study: a multicentre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26.
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumor necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003;62:1168–77.
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, BIOBADASER group. Switching TNF antagonists in patients with chronic arthritis: an observa-tional study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.
   Google Scholar
• Hyrich KI, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13–20.
   Google Scholar
• Furst DE, Gayfis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to eta-nercept: the opposite study. Ann Rheum Dis. 2007;66:893–9.
   PubMed Web of Science ®Google Scholar
• Berthelot JM, Varin S, Cormier G, Tortellier L, Guillot P, Glemarec J, et al. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine. 2007;74: 144–7.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861–74.
   Google Scholar